Drug merger not expected to have big impact on N.J.

November 24, 2015

James Hughes, dean of the Bloustein School of Planning & Public Policy at Rutgers University, also said he did not see much duplication to be cut.

“Allergan has a sales staff that deals with their specific products, and Pfizer has its staff for different products. So I would think that staff is going to stay intact,” Hughes said. “It shouldn’t have much of an impact one way or the other on New Jersey.”

Wall Street Journal, November 23

Recent Posts

NJSPL: The Potential of Participatory Budgeting Within New Jersey

Budget Cuts and Who Absorbs Them When budgets are cut, the first programs to go are those without dedicated funding or legal mandate. Many of those programs serve low-income, disabled, and vulnerable populations. New Jersey is in a period of fiscal austerity. The...

Prof. Andrews and PhD Candidate Lina Moe: Make Room for Robots

Make Room for Robots Read Article Summary As robots become increasingly common in cities, from sidewalk delivery bots and security robots to drones and autonomous vehicles, policymakers face new questions about safety, privacy, accessibility, and the use of shared...

New Jersey State Policy Lab Holds 5th Annual Internship Presentations

On Wednesday, August 5th, the New Jersey State Policy Lab hosted the end-of-summer presentations for the 2026 intern cohort at the Bloustein School of Planning and Public Policy. These presentations are the culmination of the work accomplished through the 10-week...